Ting-Jen Cheng, Ph.D.
Name Ting-Jen Cheng, Ph.D.
現任 Senior Research Specialist/Scientist
所屬單位
High-throughput screening core lab, enzyme and cell activity analysis platform, small molecule bioactivity evaluation, automated HTS experiment design and execution.

Ph.D., Life Sciences, National Tsing Hua University, Taiwan, 1999
B.Eng, Chemical Engineering, National Tsing Hua University, Taiwan, 1993
 
名片
專長

FACILITY MANAGEMENT / EXPERTISE:

  1. Management of the High-Throughput Screening Core Facility
    Our High-Throughput Screening (HTS) Core Facility offers a one-stop solution for the design and execution of HTS experiments. We support a wide range of screening formats, including RNAi, CRISPR, antibody, and enzyme variant libraries, with miniaturized liquid handling capabilities.
    For small molecule screening, we provide access to curated compound libraries－including a collection of FDA-approved drugs－designed to meet diverse research needs.
    In addition, our platform supports functional assays to evaluate the bioactivity of custom compound libraries, helping researchers expand the applications and value of their compounds.
    The facility also offers access to individual instruments and high-throughput natural product purification services, promoting broader use of advanced analytical tools.

  2. Supporting Bioactivity Analysis for Research Teams
    We support the research center's teams in bioactivity analysis, including the development of biochemical and in vivo assay systems for drug targets and the execution of drug screening. Our current services include:

    • Developing biochemical detection systems for drug targets using molecular biology and biochemical techniques (e.g., enzyme assays)
    • Designing in vivo activity detection systems to assess compound efficacy in living organisms
    • Applying assay systems for high-throughput drug screening and identification of active compounds
    • Evaluating and testing the bioactivity of small molecules and natural products
    • Assessing vaccine efficacy
 

HTS_1024[1]
EDUCATION AND POSITIONS HELD
  • 2012-present Senior research scientist, Genomics Research Center, Academia Sinica
  • 2008-2012 Associate Research scientist, Genomics Research Center, Academia Sinica
  • 2005-2008 Assistant Research scientist, Genomics Research Center, Academia Sinica
  • 2000-2005 Post-doctoral Research Associate, Keck Graduate Institute of Applied Life Science, USA
  • Tseng YW, Yang TJ, Hsu YL, Liu JH, Tseng YC, Hsu TW, Lu Y, Pan SH,* Cheng TR,* Fang JM*, 2024, “Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.”, European journal of medicinal chemistry, 265, 116042. (SCIE)
  • Wang SC, Liao HY, Zhang JY, Cheng TR,* Wong CH*, 2019, “Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris.”, Virology, 526, 125-137. (SCIE)
  • Wu WS, Cheng WC, Cheng TR,* Wong CH*, 2018, “Affinity-Based Screen for Inhibitors of Bacterial Transglycosylase.”, Journal of the American Chemical Society, 140, 2752-2755. (SCIE)
  • Huang LY, Wang SC, Cheng TR,* Wong CH*, 2017, “Undecaprenyl Phosphate Phosphatase Activity of Undecaprenol Kinase Regulates the Lipid Pool in Gram-Positive Bacteria.”, Biochemistry, 56(40), 5417-5427. (SCIE)
  • Huang LY, Huang SH, Chang YC, Cheng WC, Cheng TJ, Wong CH, 2014, “Enzymatic synthesis of lipid II and analogues.”, Angewandte Chemie-International Edition, 53, 8060-8065. (SCIE)
  • Huang SH, Wu WS, Huang LY, Huang WF, Fu WC, Chen PT, Fang JM, Cheng WC, Cheng TJ, Wong CH, 2013, “New continuous fluorometric assay for bacterial transglycosylase using forster resonance energy transfer.”, Journal of the American Chemical Society, 135(45), 17078-17089. (SCIE)
  • Liao HY, Hsu CH, Wang SC, Liang CH, Yen HY, Su CY, Chen CH, Jan JT, Ren CT, Chen CH, Cheng TJ, Wu CY, Wong CH, 2010, “Differential receptor binding affinities of influenza hemagglutinins on glycan arrays.”, Journal of the American Chemical Society, 132(42), 14849-14856. (SCIE)
  • Cheng TJ, Wu YT, Yang ST, Lo KH, Chen SK, Chen YH, Huang WI, Yuan CH, Guo CW, Huang LY, Chen KT, Shih HW, Cheng YS, Cheng WC, Wong CH, 2010, “High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase.”, Bioorganic & medicinal chemistry, 18(24), 8512-8529. (SCIE)
  • Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng WC, Wu YT, Tsai MD, Cheng YS, Wong CH, 2010, “High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity.”, Proceedings of the National Academy of Sciences of the United States of America, 107(45), 19151-19156. (SCIE)
  • Cheng TJ, Sung MT, Liao HY, Chang YF, Chen CW, Huang CY, Chou LY, Wu YD, Chen YH, Cheng YS, Wong CH, Ma C, Cheng WC, 2008, “Domain requirement of moenomycin binding to bifunctional transglycosylases and development of high-throughput discovery of antibiotics.”, Proceedings of the National Academy of Sciences of the United States of America, 105(2), 431-436. (SCIE)
這是一張圖片